Physician profile
Donald D Dangle
NPI 1003171141
$13,904.61
in general payments reported to CMS, 2019-2025
47 companies · $2,298 in 2025
The $2,298 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,266 · 2020: $1,898 · 2021: $2,529 · 2022: $1,939 · 2023: $1,905 · 2024: $2,070 · 2025: $2,298.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,273.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,272.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $3,007.75 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $1,791.89 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Glaxosmithkline, LLC. | $1,336.97 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,277.88 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $992.97 | 2019-2025 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| Pfizer INC. | $563.58 | 2019-2025 | |
| Amgen INC. | $489.46 | 2019-2024 | Evenity, Prolia, Repatha |
| Merck Sharp & Dohme LLC | $414.88 | 2019-2024 | Belsomra, Gardasil 9, Vaxneuvance |
| Dexcom, INC. | $384.70 | 2021-2025 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $383.51 | 2019-2022 | |
| Lilly USA, LLC | $354.31 | 2019-2025 | Zepbound, Jardiance, Mounjaro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $270.18 | 2019-2024 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $260.14 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $254.39 | 2019-2023 | Xarelto |
| Exact Sciences Corporation | $223.37 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Dangle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.